Full Breakdown
Trump Administration Moves Limited Marijuana Products to Schedule III
5/10/2026, 3:58:49 AM
Limited Rescheduling of Medical Cannabis to Schedule III
On April 23 2026 the Department of Justice re-classified two categories of cannabis—FDA-approved products and state-licensed medical marijuana—moving them from Schedule I to Schedule III. The order does not affect recreational cannabis and does not legalize any use federally.
Background & Context
Marijuana has been a Schedule I drug since 1970, classified alongside heroin and LSD. By June 2025, 40 states, the District of Columbia and three territories permit medical use, while 24 states, D.C. and three territories allow recreational use.
Key Actors
President Donald Trump signed the executive order enabling the DOJ change. Heather Trela, director of operations at the Rockefeller Institute of Government, explained the policy. Opposition includes Smart Approaches to Marijuana (SAM) and the National Drug and Alcohol Screening Alliance (NDASA), which filed a May 4 2026 petition.
Data & Statistics
State data show 40 states + DC + 3 territories authorize medical cannabis, and 24 states + DC + 3 territories permit recreational use. A Gallup poll in October 2025 recorded 64 % public support for legalization, down from a 70 % peak in 2023.
Impact & Implications
Reclassifying medical cannabis to Schedule III removes many research barriers, a benefit Trela called “hugely beneficial.” The shift may allow tax deductions for medical-cannabis businesses, but its effect on firms also selling recreational products remains uncertain. Federal prosecutors retain discretion to pursue recreational users, though mandatory-minimum penalties could be reduced.
Official Statements
The administration framed the change as a targeted, evidence-based step focused on products with proven medical value while preserving flexibility on broader legalization. DOJ officials stressed that only FDA-approved and state-licensed medical products qualify, and reiterated that the order does not alter the federal illegality of recreational cannabis.
Criticism & Legal Challenge
Smart Approaches to Marijuana and NDASA argue the order violates rulemaking procedures and represents an overreach, labeling the administration “the most pro-drug administration in our history.” They filed a lawsuit seeking to block the rescheduling.
Conflicting Reports & Gaps
Analysts disagree on whether the reclassification will generate tax benefits for companies that also market recreational cannabis. The DOJ’s broader rescheduling plan, slated for hearings after June 2026, lacks a detailed timetable, leaving enforcement priorities unclear.
Verbatim Quotes
- “Some people like it, some people hate it. Some people hate the whole concept of marijuana,” — President Donald Trump
- “This does not make it legal to be used in any circumstance,” — Heather Trela, Rockefeller Institute of Government
- “With this move, we are now confronted with the most pro-drug administration in our history,” — Smart Approaches to Marijuana (SAM)
- “Mostly it’s been the attitude of the federal government that this isn’t worth their time,” — Heather Trela
Outlook
The DOJ will hold administrative hearings on broader rescheduling after June 2026, a step that may prompt further lawsuits. Congress could still act to fully reschedule or legalize cannabis, though bipartisan momentum remains limited.
